Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation.
Pasvolsky O, Marcoux C, Wang Z, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Syed N, Aljawai Y, Lee HC, Patel KK, Becnel MR, Ye C, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Pasvolsky O, et al. Among authors: becnel mr. Transplant Cell Ther. 2024 Dec 31:S2666-6367(24)00841-8. doi: 10.1016/j.jtct.2024.12.023. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39746546
Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy.
Manzar GS, Dudzinski SO, Yoder AK, Seo A, Nasr LF, Rafei H, Becnel MR, Patel KK, Lee HC, Kaufman GP, Gaballa MM, Ye JC, Saini N, Thomas SK, Amini B, Orlowski RZ, Dabaja BS, Pinnix CC, Gunther JR, Wu SY, Fang PQ. Manzar GS, et al. Among authors: becnel mr. Clin Lymphoma Myeloma Leuk. 2024 Nov 22:S2152-2650(24)02422-4. doi: 10.1016/j.clml.2024.11.010. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39709251
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.
Pasvolsky O, Marcoux C, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Lee J, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Kebriaei P, Becnel MR, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Pasvolsky O, et al. Among authors: becnel mr. Blood Cancer J. 2024 Oct 31;14(1):189. doi: 10.1038/s41408-024-01165-w. Blood Cancer J. 2024. PMID: 39482325 Free PMC article.
Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy.
Fang P, Pinnix CC, Wu SY, Lee HC, Patel KK, Saini N, Becnel MR, Kaufman G, Thomas SK, Orlowski RZ, Amini B, Lin P, Dabaja BS, Gunther JR. Fang P, et al. Among authors: becnel mr. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):193-199. doi: 10.1016/j.ijrobp.2023.11.039. Epub 2023 Dec 8. Int J Radiat Oncol Biol Phys. 2024. PMID: 38070713
Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.
Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Dang M, et al. Among authors: becnel mr. Cancer Cell. 2023 Jun 12;41(6):1032-1047.e4. doi: 10.1016/j.ccell.2023.05.007. Cancer Cell. 2023. PMID: 37311413 Free PMC article.
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis.
Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SK. Shank BR, et al. Among authors: becnel mr. Clin Lymphoma Myeloma Leuk. 2023 Apr;23(4):279-290. doi: 10.1016/j.clml.2022.12.004. Epub 2022 Dec 10. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36797154 Free PMC article.
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Mohan M, et al. Among authors: becnel mr. Am J Hematol. 2022 Jul;97(7):E276-E280. doi: 10.1002/ajh.26580. Epub 2022 May 2. Am J Hematol. 2022. PMID: 35472167 Free PMC article. No abstract available.
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Becnel MR, et al. Br J Haematol. 2019 Jun;185(5):874-882. doi: 10.1111/bjh.15843. Epub 2019 Mar 28. Br J Haematol. 2019. PMID: 30919940 Free PMC article. Clinical Trial.
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS. Hill BT, et al. Among authors: becnel mr. Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21. Br J Haematol. 2019. PMID: 30575016 Free PMC article. Clinical Trial.
11 results